Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Octanedioate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 6/20 | 0.67 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 5/20 | 0.67 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.67 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.67 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.67 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.67 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 5/20 | 0.92 |
| ▸ | LMNA | P02545 | 3/20 | 0.92 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.92 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.92 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.71 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.71 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.71 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.71 |
| ▸ | PPARD | Q03181 | 6/20 | 0.67 |
| ▸ | PPARA | Q07869 | 6/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | TLR2 | O60603 | 2/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14809119 | 1.00 | TSHR (0.92) | TSHRLMNANFKB1PMP22SLC22A6 | |
| Pimelic Acid SCHEMBL5657862 | 1.00 | TSHR (0.92) | TSHRLMNANFKB1PMP22SLC22A6 | |
| Hydrochloric Acid SCHEMBL9357071 | 1.00 | TSHR (0.92) | TSHRLMNANFKB1PMP22SLC22A6 | |
| Sebacic Acid SCHEMBL14809045 | 1.00 | TSHR (0.92) | TSHRLMNANFKB1PMP22SLC22A6 | |
| Azelaic Acid SCHEMBL687821 | 1.00 | TSHR (0.92) | TSHRLMNANFKB1PMP22SLC22A6 | |
| Sebacic Acid SCHEMBL14809117 | 1.00 | TSHR (0.92) | TSHRLMNANFKB1PMP22SLC22A6 | |
| Hydrochloric Acid SCHEMBL8528394 | 1.00 | TSHR (0.92) | TSHRLMNANFKB1PMP22SLC22A6 | |
| Hydrochloric Acid SCHEMBL525656 | 1.00 | TSHR (0.92) | TSHRLMNANFKB1PMP22SLC22A6 | |
| Hydrochloric Acid SCHEMBL8920429 | 1.00 | TSHR (0.92) | TSHRLMNANFKB1PMP22SLC22A6 | |
| Hydrochloric Acid SCHEMBL8924000 | 1.00 | TSHR (0.92) | TSHRLMNANFKB1PMP22SLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202333-B2 | Aqueous solution containing bis(N epsilon lauroyllysine)dicarboxylic acid diamide and/or salt thereof, and method for producing same | AJINOMOTO CO., INC. (JP) | 2019-02-12 | — | — | US | claimed |
| US-20170260127-A1 | AQUEOUS SOLUTION CONTAINING BIS(N EPSILON LAUROYLLYSINE)DICARBOXYLIC ACID DIAMIDE AND/OR SALT THEREOF, AND METHOD FOR PRODUCING SAME | AJINOMOTO CO., INC. (JP) | 2017-09-14 | — | — | US | claimed |
| US-6075139-A | ADDING DROPWISE A WATER IMMISCIBLE ORGANIC SOLVENT CONTAINING A BIFUNCTIONAL ACIDIC REACTANT TO AQUEOUS SOLUTION OF SUCROSE, AND MAINTAINING REACTION UNTIL SUCROSE ESTER OLIGOMER OR POLYMER IS PRODUCED AT INTERFACE | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2000-06-13 | — | — | US | claimed |
| US-5739256-A | Method for making multidimensional polyester oligomers | THE BOEING COMPANY (US) | 1998-04-14 | — | — | US | claimed |
| WO-1998003528-A1 | LINEAR AND CYCLIC SUCROSE REACTION PRODUCTS, THEIR PREPARATION AND THEIR USE | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 1998-01-29 | — | — | WO | claimed |
| WO-2026100585-A1 | CURABLE RESIN COMPOSITION, PREPREG, AND CURED PRODUCTS THEREOF | 日本化薬株式会社 | 2026-05-15 | — | — | WO | disclosed |
| US-20260117059-A1 | CURABLE RESIN, CURABLE RESIN COMPOSITION, CURED PRODUCT, PREPREG, LAMINATE, AND SEMICONDUCTOR SUBSTRATE | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2026-04-30 | — | — | US | disclosed |
| US-20260109854-A1 | CURABLE RESIN COMPOSITION, AND CURED PRODUCT THEREOF | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2026-04-23 | — | — | US | disclosed |
| US-20260109853-A1 | CURABLE RESIN COMPOSITION AND CURED PRODUCT OF SAME | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2026-04-23 | — | — | US | disclosed |
| US-20260078208-A1 | COMPOUND, CURABLE RESIN COMPOSITION AND CURED PRODUCT OF SAME | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2026-03-19 | — | — | US | disclosed |
| EP-4572882-A1 | PROCESS FOR PRODUCING MICROPARTICLES | BASF SE (DE) | 2025-06-25 | — | — | EP | disclosed |
| CN-119730951-A | Method for producing microparticles | 巴斯夫欧洲公司 | 2025-03-28 | — | — | CN | disclosed |
| US-4504632-A | Amide ether imide block copolymers | GENERAL ELECTRIC COMPANY (US) | 1985-03-12 | — | — | US | disclosed |
| EP-0131925-A2 | Metal oxide having uniform pore sizes, the process for producing said metal oxide, and catalyst carrier comprising the said metal oxide | Daido Sanso K.K. (JP) | 1985-01-23 | — | — | EP | disclosed |
| US-4350781-A | Process for the preparation of polymer precursors containing oxazolin-2-one rings | BAYER AKTIENGESELLSCHAFT (DE) | 1982-09-21 | — | — | US | disclosed |
| US-4336348-A | POLYESTERS, PHASE BOUNDARIES, POLYMER IN ORGANIC PHASE | BAYER AKTIENGESELLSCHAFT (DE) | 1982-06-22 | — | — | US | disclosed |
| US-4336248-A | SUITABLE FOR BLOOD REPLACEMENTS | BIOTEST-SERUM-INSTITUT GMBH (DE) | 1982-06-22 | — | — | US | disclosed |
| US-4124651-A | Process for the production of polyamide-polyamide-acid copolymers | CIBA-GEIGY CORPORATION (US) | 1978-11-07 | — | — | US | disclosed |
| US-4092298-A | RESINOUS POLYHYDROXYL COMPOUND, BISAZLACTONE AS CROSS-LINKING AGENT | DEUTSCHE TEXACO AKTIENGESELLSCHAFT (DT) | 1978-05-30 | — | — | US | disclosed |
| US-3957607-A | Process for the preparation of lipide soluble complexes of cations, application of the process and use of the complexes | W. MOLLER GLASBLASEREI (CH) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109854-A1 | CURABLE RESIN COMPOSITION, AND CURED PRODUCT THEREOF | MLLT1, CRBN, POT1 | PPARG 3473/4885HDAC11 670/4885ESR1 385/4885 |
| US-20260117059-A1 | CURABLE RESIN, CURABLE RESIN COMPOSITION, CURED PRODUCT, PREPREG, LAMINATE, AND SEMICONDUCTOR SUBSTRATE | RAD51, ASH2L, H1-0 | PPARG 3637/4885HDAC11 1482/4885ESR1 227/4885 |
| US-20260078208-A1 | COMPOUND, CURABLE RESIN COMPOSITION AND CURED PRODUCT OF SAME | BMI1, SEM1, PSMB2 | PPARG 4103/4885HDAC11 957/4885ESR1 823/4885 |
| US-20260109853-A1 | CURABLE RESIN COMPOSITION AND CURED PRODUCT OF SAME | PSMA1, PSMB10, RAD51 | PPARG 2016/4885HDAC11 453/4885ESR1 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.